Literature DB >> 23713855

Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome.

Jason S Radowsky1, Robin S Howard, Henry B Burch, Alexander Stojadinovic.   

Abstract

BACKGROUND: The clinical importance of extrathyroidal extension (ETE) on outcome of papillary thyroid cancer (PTC), particularly with respect to disease extending to the surgical margin is not well established. This study assessed the importance of surgical margin and extrathyroidal invasion relative to local control of disease and oncologic outcome.
METHODS: A retrospective analysis of a prospective institutional endocrine database was conducted on 276 patients with PTC treated between 1955 and 2004 to determine the impact of margin-negative resection (n=199, 72%), disease up to within 1 mm of surgical margin (n=19, 7%), microscopic (n=39, 14%), and gross (n=19, 7%) ETE. Data were compared with Fisher's exact test or analysis of variance (ANOVA).
RESULTS: Median follow-up was 3.1-6.8 years per study group (disease-free survival, range 1-37 years). The proportion of those with age >45 years, prior radiation exposure, distant metastasis at presentation, and those undergoing total thyroidectomy was not significantly different between groups. Tumor size and multifocality correlated with extent of local disease, which in turn was significantly associated with regional nodal disease at time of primary operation as well as prevalence of persistence of disease after multimodality therapy. Extent of local disease correlated significantly with subsequent clinical recurrence after a disease-free period (p=0.006); however, recurrence rates were not significantly different between negative and close (≤1 mm) margin resection.
CONCLUSION: Oncological outcome correlates with the extent of extrathyroidal invasion. Outcome is worse in patients with gross extrathyroidal disease extension than in those with microscopic local invasion apparent on histopathological assessment. However, the risk of clinical recurrence appears similar between patients undergoing margin-negative and "close margin" resection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23713855     DOI: 10.1089/thy.2012.0567

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  53 in total

Review 1.  Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

Authors:  M G Castagna; S Cantara; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-06-27       Impact factor: 4.256

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 3.  Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Authors:  Bin Xu; Ronald A Ghossein
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

Review 4.  [Definition of R1 resection in thyroid carcinoma].

Authors:  S Synoracki; Ch Wittekind; H Dralle; K W Schmid
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

5.  External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.

Authors:  Ana P Kiess; Nishant Agrawal; James D Brierley; Umamaheswar Duvvuri; Robert L Ferris; Eric Genden; Richard J Wong; R Michael Tuttle; Nancy Y Lee; Gregory W Randolph
Journal:  Head Neck       Date:  2015-12-30       Impact factor: 3.147

6.  Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Authors:  Jiao Li; Jun Liang; Teng Zhao; Yansong Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-16       Impact factor: 9.236

Review 7.  Microscopic positive surgical margins in thyroid carcinoma: a proposal for thyroid oncology teams.

Authors:  Alvaro Sanabria; Luiz P Kowalski; Iain J Nixon; Ricard Simo
Journal:  Langenbecks Arch Surg       Date:  2021-02-08       Impact factor: 3.445

Review 8.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Nancy D Perrier; James D Brierley; R Michael Tuttle
Journal:  CA Cancer J Clin       Date:  2017-11-01       Impact factor: 508.702

Review 9.  [Proposal for an extended pTNM classification of thyroid carcinoma : Commentary on deficits of the 8th edition of the TNM classification (German version)].

Authors:  K W Schmid; S Synoracki; H Dralle; C Wittekind
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

10.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer.

Authors:  Sana A Ghaznavi; Ian Ganly; Ashok R Shaha; Crystal English; Jonathan Wills; R Michael Tuttle
Journal:  Thyroid       Date:  2018-08-02       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.